FoxA2

FoxA2
Name	Forkhead box A2
Alternative names	HNF-3B, TCF-3
Organism	Homo sapiens
Uniprot	P47565
Location	nucleus
Length	401 aa
Family	Forkhead box

FoxA2

Introduction

FoxA2 is a pioneering transcription factor central to vertebrate development and cellular homeostasis. It interacts with chromatin and regulatory networks involving Francis Crick, Sydney Brenner, Howard Temin, James Watson, Rosalind Franklin-style paradigms in molecular biology and has been studied by groups at institutions such as Harvard University, Massachusetts Institute of Technology, Stanford University, University of Cambridge, and Max Planck Society. Its study intersects with landmark concepts exemplified by work at the National Institutes of Health, the Wellcome Trust, the Howard Hughes Medical Institute, the European Molecular Biology Laboratory, and major consortia like the ENCODE Project.

Gene and Protein Structure

The FOXA2 gene encodes a 401–amino-acid protein with a characteristic winged-helix forkhead DNA-binding domain first characterized during comparative studies by researchers affiliated with Cold Spring Harbor Laboratory, Salk Institute, and the University of California, San Diego. Structural analyses using techniques developed at European Synchrotron Radiation Facility, Brookhaven National Laboratory, and cryo-EM groups at EMBL-EBI revealed a compact forkhead fold enabling pioneer factor activity, similar in motif organization to family members studied at University of Oxford and University of Tokyo. The gene locus on chromosome 20 is annotated in resources maintained by Ensembl, GenBank, and the UCSC Genome Browser, and includes conserved promoter elements and potential enhancer contacts mapped by projects from Broad Institute, Wellcome Sanger Institute, and Genome Research Limited.

Expression and Regulation

FOXA2 expression is tightly regulated by signaling pathways characterized in studies at Dana-Farber Cancer Institute, Johns Hopkins University, Yale University, Columbia University, and University College London. Upstream regulators include factors identified in developmental atlases generated by the Allen Institute for Brain Science and datasets from the Human Cell Atlas. Post-translational modifications such as phosphorylation, acetylation, and ubiquitination have been documented in proteomics screens by teams at ProteomeXchange, European Proteomics Infrastructure, and Thermo Fisher Scientific-supported laboratories; regulatory interactions involve proteins studied at MIT Koch Institute, Karolinska Institutet, University of Pennsylvania, and McGill University.

Biological Functions

FOXA2 acts as a pioneer transcription factor opening compacted chromatin to enable recruitment of lineage-specific regulators—a principle explored in landmark labs at UC Berkeley, Princeton University, University of Chicago, and University of California, Los Angeles. Its downstream targets include genes implicated in metabolic control and secretory programs characterized in studies at Rockefeller University, Imperial College London, University of Michigan, and ETH Zurich. Functional assays employing approaches from Cold Spring Harbor Laboratory, EMBO, and major pharmaceutical research units at Pfizer, Novartis, and GlaxoSmithKline have shown roles in maintaining epithelial identity, regulating glucose homeostasis, and orchestrating cell polarity.

Role in Development and Organogenesis

During embryogenesis FOXA2 is essential for endoderm specification and floor plate formation as demonstrated in classical experiments performed at Princeton University, University of Cambridge, Stanford University School of Medicine, and Scripps Research. Its requirement in liver, lung, and pancreas organogenesis was delineated using mouse models generated by groups at The Jackson Laboratory, European Molecular Biology Laboratory, Monash University, and University of Toronto. Interactions with morphogen pathways—such as signaling components studied at Max Planck Institute for Developmental Biology, Whitehead Institute, Institute of Molecular Biology (IMB) Mainz—and crosstalk with transcriptional hierarchies investigated at Johns Hopkins Medicine and Vanderbilt University position FOXA2 as a core organizer of tissue-specific transcriptional programs.

Clinical Significance and Disease Associations

Altered FOXA2 function has been linked to metabolic disorders, congenital malformations, and cancers reported in clinical studies from Mayo Clinic, Cleveland Clinic, UCSF Medical Center, Mount Sinai Hospital, and multicenter consortia including The Cancer Genome Atlas and International Cancer Genome Consortium. Mutations, epigenetic silencing, and dysregulated expression correlate with phenotypes cataloged in databases curated by ClinVar, OMIM, and HGNC; associations include hepatobiliary dysfunction, neonatal diabetes syndromes, and lung developmental defects characterized in pediatric studies at Great Ormond Street Hospital. FOXA2 modulation is also implicated in tumor suppression and oncogenic programs across hepatocellular carcinoma, pancreatic adenocarcinoma, and lung adenocarcinoma cohorts analyzed by consortia at MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute.

Experimental Models and Research Tools

Research on FOXA2 employs genetically engineered mouse models from The Jackson Laboratory, conditional alleles produced using CRISPR methods pioneered at Broad Institute and Zuckerberg San Francisco General Hospital collaborations, and human cellular models derived using protocols from Stem Cell Institute, Karolinska Institutet, and Riken Center for Developmental Biology. Chromatin assays, ChIP-seq, ATAC-seq, and single-cell transcriptomics leveraging platforms developed by Illumina, 10x Genomics, PacBio, and computational tools from Galaxy Project and Bioconductor have been widely used. Reagents and antibodies validated by groups at Abcam, Cell Signaling Technology, and repositories like Addgene support mechanistic and translational studies.

Category:Transcription factors